BGMA Warns No-Deal Brexit Will Harm Depleted UK Stockpile
As European Governments Brace For Possible Second Wave Of COVID-19
While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.
You may also be interested in...
New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic eﬀectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.
The BGMA has emphasized the importance of prioritizing transport of medicines across borders, at the same time as it has praised decisions by the UK competition authority and European Commission to relax rules on co-ordinating to facilitate the supply of medicines.